Adding Bevacizumab to Olaparib Boosts Survival Only in BRCA-Mutated Ovarian Cancer
A real-world study of 214 patients finds that adding Bevacizumab to Olaparib maintenance therapy significantly improves overall survival only in ...
A real-world study of 214 patients finds that adding Bevacizumab to Olaparib maintenance therapy significantly improves overall survival only in ...
Researchers built an explainable random survival forest model that predicts overall and cancer-specific survival in postoperative gastrointestinal stromal tumor patients, ...
A propensity score-matched study of 153 patients suggests adjuvant radiotherapy does not improve overall or recurrence-free survival in limb liposarcoma, ...
A ten-year single-center study reports 94 percent primary efficacy and 100 percent cancer-specific survival at five years for image-guided ablation ...
A retrospective Chinese study finds that adding the PD-1 inhibitor tislelizumab to paclitaxel-carboplatin chemotherapy and bevacizumab significantly improves response rates, ...
A multicenter study of 167 lung cancer patients found that persistent emotional distress across neoadjuvant therapy and surgery was independently ...
In the ongoing battle against prostate cancer, particularly in its metastatic castration-sensitive form, an emerging conversation has transpired regarding the ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.